Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Real‐world, long‐term treatment patterns of commonly used biologics in Canadian patients with moderate‐to‐severe chronic plaque psoriasis

Published:2021-11-07 Issue:1 Volume:49 Page:95-105
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Gooderham Melinda J.¹²³,Lynde Charles¹⁴⁵,Turchin Irina¹⁶⁷,Avadisian Miriam⁸,Labelle Melanie⁸,Papp Kim A.¹⁹

Affiliation:

1. Probity Medical Research Inc. Waterloo Ontario Canada

2. SkiN Centre for Dermatology Peterborough Ontario Canada

3. Queen’s University Kingston Ontario Canada

4. Lynderm Research Inc. Markham Ontario Canada

5. University of Toronto Toronto Ontario Canada

6. Brunswick Dermatology Center Fredericton New Brunswick Canada

7. Department of Medicine Dalhousie University Halifax Nova Scotia Canada

8. AbbVie Corporation Saint‐Laurent QC Canada

9. K. Papp Clinical Research Waterloo Ontario Canada

Funder

AbbVie

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.16214

Reference42 articles.

1. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

2. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

3. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction

4. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

5. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Age affects drug survival rates of interleukin (IL)‐17 and IL‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study;Journal of the European Academy of Dermatology and Venereology;2024-06-11

2. Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study;Journal of the American Academy of Dermatology;2024-06

3. Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan;Experimental Dermatology;2024-05

4. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis;Drugs;2024-04-17

5. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT‐1);Journal of the European Academy of Dermatology and Venereology;2024-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3